Table. 2—

2 Outcomes

Bosentan-treated PPH patients
Subjects n169
Duration of observation for survival
 Mean±sd2.1±0.5 yrs
 Range0.1–3.3 yrs
Patients lost to follow-up1
Lung transplantations3
Deaths n (%)20 (12)#
Transfers to/additions of prostanoids or alternative oral PPH therapies n (%)39 (23)
 Patients who received alternative treatment19
 in addition to bosentan
Discontinuations of bosentan without other event or treatment4
  • PPH: primary pulmonary hypertension. #: includes the one patient lost to follow-up; : includes the one patient lost to follow-up and three patients with a period of unknown treatment.